Urokinase-type plasminogen activator is activated in stratum corneum after barrier disruption

Journal of Dermatological Science

Volumn 32, Issue 1, 2003, Pages 55-57

  Katsuta, Yuji ^a   Yoshida, Yuzo ^a   Kawai, Eriko ^a   Kohno, Yoshiyuki ^a   Kitamura, Kenji ^a  

^a SHISEIDO RESEARCH CENTER   (Japan)

Author keywords

Barrier recovery; Stratum corneum; Urokinase type plasminogen activator

Indexed keywords

ENZYME ANTIBODY; ENZYME PRECURSOR; PLASMINOGEN ACTIVATOR; PROTEINASE; UROKINASE;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; EPIDERMIS; FIBRINOLYSIS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; SKIN PROTECTION; STRATUM CORNEUM; TISSUE HOMOGENATE; ZYMOGRAPHY;

EID: 0038209029     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0923-1811(03)00047-1     Document Type: Article

References (3)

1. Denda M., Kitamura K., Elias P.M., Feingold K.R. Trans-4-(aminomethyl)cyclohexanecarboxylic acid (t-AMCHA), an anti-fibrinolytic agent, accelerates barrier recovery and prevents the epidermal hyperplasia induced by epidermal injury in hairless mice and humans. J. Invest. Dermatol. 109:1997;84-90.
2. Kitamura K., Yamada K., Ito A., Fukuda M. Research on the mechanism by which dry skin occurs and the development of an effective compound for its treatment. J. Soc. Cosmet. Chem. 29:1995;133-145.
3. Kitamura K., Ito A., Yamada K., Yoshida Y., Fukuda M. Potential medication for skin care - focusing on the development of a new effective compound for dry skin. Skin: interface of a living system. 1998;151-166 Elsevier, Amsterdam.